

Q218—public flotation jackpot


Laura DeFrancesco

This quarter the initial public offering (IPO) market set records for the amount of money raised while other financings dropped slightly from previous quarters. Much of the bonanza came from the East: Chinese biotechs increasingly contributed to the global picture. A notable

number of venture capital investments (3 out of the top 10) went into precision medicine diagnostics, a sector traditionally lacking funding. Two startups developing RNA-targeted therapies were among the top 10 deals.


Stock market performance

The peak biotech stock index in 2Q18 was within a few percentage points of its historic high from mid-2015.



Global biotech initial public offerings


All regions showed robust IPO activity.



Source: BCIQ: BioCentury Online Intelligence.

Global biotech venture capital investment


The venture capital bonanza continues, with funds still pouring in, especially from China.



Source: BCIQ: BioCentury Online Intelligence.

Global biotech financing

Last quarter saw the least debt financing and partnership money of any of the past seven quarters.*Total deal value



Notable 2Q18 deals

Initial public offerings

Company name	Date completed	Amount raised (\$ millions)	Change in stock since offer (as of 8/7/2018)
WuXi AppTec	07-May	353.7	57
Tricida	27-Jun	222.3	-8
Autolus Therapeutics	22-Jun	172.5	2
Kiniksa Pharmaceuticals	23-May	170.7	-29
Polyphor	15-May	165.3	-14
Eidos Therapeutics	19-Jun	122.2	-35
Translate Bio	27-Jun	121.6	-11

Venture capital rounds

Company name	Date completed	Amount raised (\$ millions)	Round number
Allogene Therapeutics	03-Apr	300	A
Grail	21-May	300	C (oversubscribed)
CStone Pharmaceuticals	08-May	260	B
Brii Biosciences	24-May	260	Not specified
I-Mab Biopharma	29-Jun	220	B
Helix Opco	28-Jun	200	B
Innovato Biologics	26-Apr	150	E
Tessa Therapeutics	12-Apr	130	Not specified

Mergers and acquisitions

Target	Acquirer	Value (\$ millions)	Date announced
AveXis	Novartis	8,700	09-Apr
Foundation Medicine	Roche	2,400	19-Jun
Abaxis	Zoetis	2,000	15-May
Wilson Therapeutics	Alexion Pharmaceuticals	848	11-Apr
Exosome Diagnostics	Bio-Techne	250	25-Jun
BeneVir Biopharm	Johnson & Johnson	140	02-May
AurKa Pharma	Eli Lilly	110	14-May
Edico Genome	illumina	100	15-May
Myonex Therapeutics	Sarepta Therapeutics	60	03-May

Deals

Researcher	Investor	Upfront Deal description cash
Sage Therapeutics	Shionogi	90 Sage grants Shionogi exclusive rights in Japan, Taiwan and South Korea to SAGE-217, a next-generation GABAA positive allosteric small-molecule modulator to treat major depressive disorder
Skyhawk Therapeutics	Celgene	60 Skyhawk grants Celgene an exclusive option to license worldwide rights to RNA-targeting small molecules identified by Skyhawk in up to five neurology programs
Translate Bio	Sanofi	45 Translate Bio partners with Sanofi's Pasteur division to develop mRNA vaccines against up to five undisclosed pathogens to treat infectious diseases
Blueprint Medicines	CStone Pharmaceuticals	40 Blueprint Medicines grants CStone Pharmaceuticals exclusive rights to develop and commercialize anticancer small-molecule candidates avapritinib, BLU-667 and BLU-554 in mainland China, including Hong Kong and Macau, and Taiwan
Arbutus Biopharma	Roivant Sciences	38 Arbutus Biopharma and Roivant Sciences forming JV Genevant Sciences to focus on the discovery, development and commercialization of RNA-based therapeutics delivered via Arbutus's lipid nanoparticle and ligand conjugate technology
Oxford BioMedica	Axovant Sciences	30 Oxford BioMedica grants Axovant exclusive, worldwide rights to develop and commercialize lentiviral delivered gene therapies OXB-102 and ProSavin to treat Parkinson's disease
Zymeworks	Daiichi Sankyo	18 Zymeworks grants Daiichi Sankyo rights to its Azymetric and EFECT platforms exploiting modular heterodimeric Fc variants with improved stability and purity to develop two bispecific antibodies
Agios Pharmaceuticals	CStone Pharmaceuticals	12 Agios Pharmaceuticals grants CStone Pharmaceuticals exclusive rights to develop and commercialize in China (Mainland, Hong Kong, Macau and Taiwan) the small molecule Tibsovo (ivosidenib), an inhibitor of mutant isocitrate dehydrogenase, as a monotherapy or in combination therapies for cancer

Source: BCIQ: BioCentury Online Intelligence.

Laura DeFrancesco is Senior Editor at Nature Biotechnology.